(Information submitted by the signing company)
TOP-REAL is evaluating whether a digital monitoring system can support earlier identification of toxicities and thus maintain the continuity of one of the most effective treatments against metastatic HER2-positive breast cancer.
This international academic study, coordinated in Spain by Solti together with Unicancer (France) and WSG (Germany), has presented at the ESMO AI & Digital Oncology 2026 congress a design that incorporates digital tools to monitor symptoms and physiological changes between in-person visits.
TOP-REAL proposes a proactive monitoring model to determine whether an early detection of toxicities can prevent these from forcing interruption of first-line treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab.
The follow-up plan integrates results reported by the patients themselves through electronic means (ePRO), pulse oximetry, and continuous recording of physiological parameters via smartwatches; the system generates alerts that enable earlier clinical assessment.
The trial provides for the participation of about 300 people across 60 centers in Spain, France and Germany. The goal is to obtain evidence in a broad and representative cohort of daily clinical practice, incorporating profiles that are typically underrepresented in pivotal trials, such as patients with active brain metastases or with an ECOG 2 functional status.
BARCELONA, Spain, November 20, 2026 /PRNewswire/ -- Solti, an academic group dedicated to clinical cancer research, has unveiled at the European congress ESMO AI & Digital Oncology 2026 the design of TOP-REAL, an international academic Phase II study that analyzes a proactive monitoring model in patients with advanced or metastatic HER2-positive breast cancer treated in first line with trastuzumab deruxtecan (T-DXd) plus pertuzumab.
The project incorporates digital solutions to extend observation of the patients beyond hospital visits, with the aim of determining whether the identification of symptoms and physiological changes enables faster assessment and a more timely approach to toxicities, before they worsen and put treatment continuity at risk.
"We want patients not only to benefit from advances that allow better control of their disease, but also to live better during treatment. Ultimately, TOP-REAL was conceived with a dual objective: to improve clinical outcomes and place patients' quality of life at the center of care", explained Dr. Cristina Saura, principal investigator of TOP-REAL, a member of the Board of Directors of Solti, head of the Breast Cancer Unit at Hospital Universitario Vall d'Hebron, and head of the Breast Cancer Group of VHIO.
Driven by the Spanish organization Solti, TOP-REAL envisages the inclusion of about 300 patients and is already being developed in the three participating countries: Spain, France and Germany. In Spain and France there are already patients under follow-up, while in Germany recruitment continues. The study is carried out in collaboration with the academic groups Unicancer (France) and WSG (Germany).
Making visible what happens between visits
The progressive improvement in the effectiveness of treatments against HER2-positive breast cancer has placed the management of toxicity as an increasingly relevant aspect within the overall therapeutic benefit. Adverse events can deteriorate quality of life and, in some cases, force dose adjustments, temporarily interrupt treatment, or even definitively discontinue it.
"Precisely because treatments are increasingly effective and allow patients to live longer, we must pay growing attention to how they live during that period", added Dr. Saura.
Among the toxicities that TOP-REAL will analyze specifically is interstitial lung disease or pneumonitis associated with T-DXd. The protocol includes daily measurements of oxygen saturation by pulse oximetry and periodic exercise tests, with the intention of determining whether certain changes could justify an earlier medical assessment. This approach is exploratory in nature.
A cohort aligned with real clinical practice
TOP-REAL will incorporate profiles that often remain underrepresented in pivotal trials, such as certain patients with active brain metastases or with an ECOG 2 functional status, with the aim of obtaining data in a population closer to real-world care.
Dr. Santiago Escrivà, principal investigator of TOP-REAL, medical oncologist at the Vall d'Hebron University Hospital and researcher of the VHIO Breast Cancer Group, has assessed what additional information this work can provide with respect to the trials that have already demonstrated the efficacy of the combination T-DXd and pertuzumab: "The TOP-REAL trial contributes to the implementation of trastuzumab deruxtecan and pertuzumab in a real-world clinical practice setting; it is a treatment with unprecedented efficacy. It allows us to better understand how to deliver this therapy to a broader range of patient profiles and optimize the management of potential toxicities, leveraging digital tools to preserve and improve their quality of life."
TOP-REAL will measure the benefit of the treatment and its continuation over time until the administration of a subsequent anti-cancer therapy, as well as health-related quality of life, including changes in physical functioning through the EORTC QLQ-C30 questionnaire, a standard tool in oncology for assessing different dimensions of quality of life.
European collaboration to bring innovation to the clinic
Professor Nadia Harbeck, principal investigator of TOP-REAL and director of the Breast Center of the Department of Obstetrics and Gynecology and of the Comprehensive Cancer Center of Munich at the LMU University Hospital in Munich (Germany), has highlighted the international dimension of the initiative.
In addition to focusing on the management of toxicity and quality of life, TOP-REAL will analyze the feasibility and safety of re-administering T-DXd rechallenge in selected patients, and will incorporate the study of tumor biopsies and blood samples to investigate biomarkers associated with both treatment response and toxicity.
Digital monitoring with a patient-focused approach
TOP-REAL integrates a mobile application —CANKADO or Resilience, depending on the country and center—, electronically reported outcomes by patients (ePROs), pulse oximetry, and monitoring via smartwatches. These resources allow patients to report symptoms and physiological variations between visits and, depending on the platform, may generate automated recommendations or alerts.
"Detecting toxicity early can make a significant difference in a patient's experience during treatment. We want to move from a model in which we wait for the patient to inform us of a problem when she comes to the appointment, to another in which we can anticipate setbacks, provide closer follow-up, and help her manage side effects better," added Dr. Saura.
(CONTINUES)